Author

Reinhard von Roemeling

Observed names: R Roemeling, R V Roemeling, R von Roemeling, R. Roemeling, R. V. Roemeling, R. Von Roemeling, R. von Roemeling, R.V. Roemeling, R.v. Roemeling, REINHARD VON ROEMELING, Reinhard Roemeling, Reinhard V. Roemeling, Reinhard Von Roemeling

Observed institutions: Poznan University of Medical Sciences, University of Minnesota, Fairview Health Services, Royal Adelaide Hospital, Memorial Sloan Kettering Cancer Center, Daiichi Sankyo (Germany), Friedrich-Alexander-Universität Erlangen-Nürnberg, Ludwig Cancer Research, Aix-Marseille Université, Royal Prince Alfred Hospital, Peter MacCallum Cancer Centre, Sahlgrenska University Hospital, Monash Medical Centre, Medizinische Hochschule Hannover, Assistance Publique Hôpitaux de Marseille, Universitätsklinikum Erlangen, Daiichi-Sankyo (Japan), Ludwig Cancer Research, Istituto Oncologico Veneto, Sanofi (United States), Ludwig Cancer Research, Ludwig Cancer Research, Asklepios Fachkliniken München-Gauting, Curis (United States), University of Minnesota Medical Center, LungenClinic Grosshansdorf, Neovii Biotech (Germany), Center for Cancer Research, Boehringer Ingelheim (United States), Daiichi Sankyo (United States), Austin Health, Masonic Cancer Center, Albany Medical College, University of Turin, Drexel University, Albany Medical Center Hospital, University of Pennsylvania

OpenAlex ID: A5013979917

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

2012 · Armando Santoro, Lorenza Rimassa, et al. · The Lancet Oncology · 554

Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group

2000 · Joachim von Pawel, Reinhard von Roemeling, et al. · Journal of Clinical Oncology · 285

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer

2015 · Giorgio Scagliotti, Joachim von Pawel, et al. · Journal of Clinical Oncology · 265

PDF

Phase I Trial of Concurrent Tirapazamine, Cisplatin, and Radiotherapy in Patients With Advanced Head and Neck Cancer

2001 · Danny Rischin, Lester Peters, et al. · Journal of Clinical Oncology · 201

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

2012 · Giorgio V. Scagliotti, Silvia Novello, et al. · Clinical Lung Cancer · 126

Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial

2013 · R. C. Smallridge, J. A. Copland, et al. · The Journal of Clinical Endocrinology & Metabolism · 113

Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.

1990 · W J Hrushesky, R von Roemeling, et al. · Journal of Clinical Oncology · 113

Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer.

1989 · R von Roemeling, W J Hrushesky · Journal of Clinical Oncology · 101

Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer

2013 · Andres Forero‐Torres, Jeffrey R. Infante, et al. · Cancer Medicine · 92

PDF

Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study

1998 · Ding-Jen Lee, Andy Trotti, et al. · International Journal of Radiation Oncology*Biology*Physics · 81

PDF

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy

2016 · Cathy Eng, Alberto Bessudo, et al. · International Journal of Cancer · 72

PDF

Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study.

1998 · J Treat, E Johnson, et al. · Journal of Clinical Oncology · 64

Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer

1997 · V.A. Miller, K.K. Ng, et al. · Annals of Oncology · 59

Muscle cramping in phase i clinical trials of tirapazamine (SR 4233) with and without radiation

1994 · Nancy Doherty, Steven L. Hancock, et al. · International Journal of Radiation Oncology*Biology*Physics · 57

Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses

2021 · Daniel J. Landsburg, Stefan K. Barta, et al. · British Journal of Haematology · 50

PDF

Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks.

1997 · S Senan, R Rampling, et al. · PubMed · 48

Determination of the Therapeutic Index of Floxuridine by Its Circadian Infusion Pattern

1990 · R. von Roemeling, W. J. M. Hrushesky · JNCI Journal of the National Cancer Institute · 47

Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors.

1997 · C A Johnson, D Kilpatrick, et al. · Journal of Clinical Oncology · 42

Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial

1997 · Martin A. Graham, Suresh Senan, et al. · Cancer Chemotherapy and Pharmacology · 38

Comparison of Urinary Desmosine Excretion in Patients with Chronic Obstructive Pulmonary Disease or Cystic Fibrosis

2000 · DC Bode, ED Pagani, et al. · Pulmonary Pharmacology & Therapeutics · 37

IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies

2023 · Ricardo D. Parrondo, Madiha Iqbal, et al. · Frontiers in Immunology · 36

PDF

Mandibular myelosarcoma (chloroma): Primary oral manifestation of promyelocytic leukemia

1984 · P.A. Reichart, R.v. Roemeling, et al. · Oral Surgery Oral Medicine Oral Pathology · 35

Tirapazamine-cisplatin: the synergy

1998 · U Gatzemeier, G Rodriguez, et al. · British Journal of Cancer · 34

PDF

Phase I Study of Tirapazamine and Cisplatin in Patients with Recurrent Cervical Cancer

1997 · Carol Aghajanian, Carol Brown, et al. · Gynecologic Oncology · 32

Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma

1997 · A.Y. Bedikian, S.S. Legha, et al. · Annals of Oncology · 29

PDF

Works count: 109

Citation count: 3,059

H-index: 26

I10-index: 46